10th November, 2025

Production Operator

7th July, 2025

Media Release: Atmo Biosciences and RMIT University granted US patent for Ingestible Gas Sensor Capsule

MELBOURNE AND SYDNEY AUSTRALIA, 15 September 2022: Atmo Biosciences, a clinical stage gut health com...

7th July, 2025

Media Release: Positive Atmo Capsule Clinical Trial Results Published

MELBOURNE AND SYDNEY AUSTRALIA, 5 October 2022: Atmo Biosciences, a clinical stage gut health compan...

7th July, 2025

Media Release: Atmo Biosciences strengthens executive leadership team and Board of Directors

MELBOURNE AND SYDNEY AUSTRALIA, 5 May 2022: Atmo Biosciences Limited, a digital health company devel...

7th July, 2025

Media Release: Atmo Biosciences Appoints Medical Advisory Board

MELBOURNE AND SYDNEY AUSTRALIA, 26 July 2022: Atmo Biosciences, a digital health company developing ...

7th July, 2025

Media Release: Atmo Biosciences closes fully subscribed $8 million Series B funding round

• Capital raise led by existing shareholder Otsuka Pharmaceutical, a leading Japanese pharmaceutical...

7th July, 2025

Media Release: Atmo Biosciences reaches 60 per cent recruitment target in dysmotility pivotal clinical study

• 85 patients recruited in multi-site clinical trial to support a submission for initial U.S. regula...

7th July, 2025

Media Release: Atmo Biosciences recruits first patients in dysmotility pivotal clinical study

• Multi-site clinical trial will support an initial submission for U.S. regulatory clearance around ...

7th July, 2025

Media Release: Atmo Biosciences appoints world-renowned gastroenterologist Professor Eamonn Quigley as Medical Advisory Board Chair

• U.S.-based Professor Quigley brings decades of experience in gastroenterological clinical practice...

7th July, 2025

Media Release: Atmo Biosciences strengthens U.S. focus with new board appointment and establishment of San Diego office

MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 17 April 2023: Atmo Biosciences, a company commercializing th...